Armistice Capital, LLC Acquires 9.75% Stake in Sangamo Therapeutics, Inc. (SGMO)

On May 15, 2026, Armistice Capital, LLC and its managing member Steven Boyd filed a Schedule 13G disclosing a significant new position in Sangamo Therapeutics, Inc. (SGMO). As of the event date of March 31, 2026, the reporting persons beneficially own 40,400,067 shares of common stock, representing a 9.75% ownership stake in the company. The shares are held directly by Armistice Capital Master Fund Ltd., for which Armistice Capital, LLC serves as the investment manager. Under an Investment Management Agreement, Armistice Capital exercises shared voting and dispositive power over these securities. Steven Boyd, in his capacity as the managing member of Armistice Capital, is also deemed to have beneficial ownership. The filing indicates that these shares were acquired in the ordinary course of business and not for the purpose of influencing or changing the control of the issuer. This filing marks a major increase from a previous 0% position, establishing Armistice Capital as a substantial institutional shareholder in the biotechnology firm.